Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.16 EUR | +0.64% | -1.22% | -10.37% |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Mar. 18 | Fresenius Settles With Johnson & Johnson to Market Stelara Alternative | DJ |
Evolution of the average Target Price on Fresenius SE & Co. KGaA
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Fresenius SE & Co. KGaA
BERENBERG | Victoria Lambert |
DEUTSCHE BANK RESEARCH | Falko Friedrichs |
UBS | Graham Doyle |
alphavalue | Martin Schnee |
BARCLAYS | Hassan Al-Wakeel |
WARBURG RESEARCH | Christian Ehmann |
JEFFERIES | James Vane-Tempest |
JPMORGAN | David Adlington |
DZ BANK | Sven Kürten |
MORGAN STANLEY | Robert Davies |
GOLDMAN SACHS | Richard Felton |
CREDIT SUISSE | Christoph Gretler |
BERNSTEIN RESEARCH | Lisa Bedell Clive |
DEUTSCHE BANK | Falko Friedrichs |
NORDLB | Holger Fechner |
INDEPENDENT RESEARCH | Tobias Gottschalt |
KEPLER CHEUVREUX | Oliver Reinberg |
HSBC | Richard Latz |
EPS Revisions
- Stock
- Equities
- Stock Fresenius SE & Co. KGaA - Xetra
- Consensus Fresenius SE & Co. KGaA